These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 26869689)

  • 1. Projecting the epidemiological effect, cost-effectiveness and transmission of HIV drug resistance in Vietnam associated with viral load monitoring strategies.
    Pham QD; Wilson DP; Nguyen TV; Do NT; Truong LX; Nguyen LT; Zhang L
    J Antimicrob Chemother; 2016 May; 71(5):1367-79. PubMed ID: 26869689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.
    Nichols BE; Sigaloff KC; Kityo C; Hamers RL; Baltussen R; Bertagnolio S; Jordan MR; Hallett TB; Boucher CA; de Wit TF; van de Vijver DA
    J Int AIDS Soc; 2014; 17(1):19164. PubMed ID: 25491351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
    Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
    Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software tool.
    Estill J; Salazar-Vizcaya L; Blaser N; Egger M; Keiser O
    PLoS One; 2015; 10(3):e0119299. PubMed ID: 25793531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
    Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
    Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the Cost-Effectiveness of HIV Prevention Programmes in Vietnam, 2006-2010: A Modelling Study.
    Pham QD; Wilson DP; Kerr CC; Shattock AJ; Do HM; Duong AT; Nguyen LT; Zhang L
    PLoS One; 2015; 10(7):e0133171. PubMed ID: 26196290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
    Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
    HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study.
    Zhang L; Phanuphak N; Henderson K; Nonenoy S; Srikaew S; Shattock AJ; Kerr CC; Omune B; van Griensven F; Osornprasop S; Oelrichs R; Ananworanich J; Wilson DP
    Lancet HIV; 2015 May; 2(5):e200-7. PubMed ID: 26423002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-financing for viral load monitoring during the course of antiretroviral therapy among patients with HIV/AIDS in Vietnam: A contingent valuation survey.
    Nguyen QL; Nguyen LH; Tran BX; Phan HT; Le HT; Nguyen HD; Tran TD; Do CD; Nguyen CM; Thuc VT; Latkin C; Zhang MW; Ho RC
    PLoS One; 2017; 12(2):e0172050. PubMed ID: 28199405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
    Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings.
    Cambiano V; Bertagnolio S; Jordan MR; Lundgren JD; Phillips A
    J Infect Dis; 2013 Jun; 207 Suppl 2():S57-62. PubMed ID: 23687290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Field performance and cost-effectiveness of a point-of-care triage test for HIV virological failure in Southern Africa.
    Saura-Lázaro A; Bock P; Bogaart EVD; van Vliet J; Granés L; Nel K; Naidoo V; Scheepers M; Saunders Y; Leal N; Ramponi F; Paulussen R; de Wit TR; Naniche D; López-Varela E
    J Int AIDS Soc; 2023 Oct; 26(10):e26176. PubMed ID: 37803882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
    Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
    Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012.
    Yang WL; Kouyos R; Scherrer AU; Böni J; Shah C; Yerly S; Klimkait T; Aubert V; Furrer H; Battegay M; Cavassini M; Bernasconi E; Vernazza P; Held L; Ledergerber B; Günthard HF;
    J Infect Dis; 2015 Jul; 212(1):28-38. PubMed ID: 25576600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of pre-treatment and acquired HIV drug resistance in Vietnam: a nationally representative survey, 2017-2018.
    Dat VQ; Anh NTL; Van Nghia K; Linh NT; Thu HHK; Tam TTM; Ton T; Anh LQ; Phuc ND; Huong PTT; Nhan DT; Hai NH; Bertagnolio S; Crisp AM; Inzaule S; Dean NE; Jordan MR; Nguyen VTT
    J Int AIDS Soc; 2022 Feb; 25(2):e25857. PubMed ID: 35194954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
    Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
    Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the impact of antiretroviral use in resource-poor settings.
    Baggaley RF; Garnett GP; Ferguson NM
    PLoS Med; 2006 Apr; 3(4):e124. PubMed ID: 16519553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
    Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.